Over the past 12 months, XCO Tech Inc. (Penticton, British Columbia) has been a proud member of the Information Technology for European Advancement (ITEA) Patient-care Advancement with Responsive Technologies aNd Engagement togetheR (PARTNER) project group. The ITEA PARTNER project group offers solutions to support the optimal patient journey through the health system for appropriate, personalized care. As part of this international digital health initiative, XCO is positioned to deliver its novel XPSTM and BioAnalyticsTM technology solutions to more than 40 European economies and over 500 million consumers.
The ITEA PARTNER project includes 19 partners based in Belgium, the Republic of Korea, the Netherlands and Canada and includes large companies such as Siemens Healthcare and Barco N.V. The consortium will focus on the key challenges in the monitoring and treatment of patients with chronic diseases. These include:
- fragmented data collection that is distributed over multiple medical disciplines
- poorly accessible data across medical centres
- lack of continuous monitoring and care outside of medical care centres
Consortium goals and activities
The goal of the PARTNER project is to develop a system of digital technology innovations to guide a patient through the health system. Continuous, seamless data will be collected and effortlessly shared across the interdisciplinary health team, ultimately leading to enhanced patient wellness. Rapid, collaborative workflows such as this are particularly important in the management of frailty and chronic diseases including heart failure, atrial fibrillation and for patients diagnosed with aortic stenosis (AS) receiving transcatheter aortic valve implantation (TAVI) surgical intervention.
Currently, heart failure (HF) affects over 40 million individuals globally, and the mortality rate is high. The overall economic burden of HF is estimated at over $100 billion per year, including both direct and indirect costs. Frailty is a syndrome with a high prevalence in older individuals that can result in a 6x increase in healthcare costs. Aortic stenosis is the most common valvular pathology in older adults with a prevalence of approximately 10% in those older than 80y and has a mortality rate of approximately 50% within 12-18 months following diagnosis. With an aging and rapidly expanding global population these values will continue to rise unless an effective solution is implemented.
XCO’s patent-pending technology will play a crucial patient measurement and analysis role in the development of this solution. The system uses ultrawideband (UWB) technology and consists of a local tracking hub and a wearable device that allows data to be captured from biometric sensors worn by the patient (e.g., ECG device, heart rate monitor, etc.). The company’s market-leading precision wireless motion tracking and biometric monitoring systems will improve on today’s subjective assessment protocols.
In the first year of the PARTNER project, XCO has designed a frailty assessment index for an individual with heart failure, including gait speed and positional markers from a walk test, and ECG data capture through a wearable monitor (imec, Eindhoven, Netherlands). The company has also developed an open API that relays relevant data to the cloud for integration into a patient portal accessible by the team of healthcare professionals overseeing treatment. This form of care, based on the “connected patient” concept, is revolutionary and is poised to dramatically improve patient care and drastically reduce the global economic burden of frailty, HF and TAVI patients.
This upcoming year will see the index expand to include the following assessments in collaboration with various partners within the project:
- heart rate variability
- cognitive function
The Canadian institutions will be collaborating with companies across Europe to commercialize their innovative technologies. The four industry partners in Canada include XCO Tech Inc., Calgary Scientific Inc., Dapasoft Inc. and iClinic.
The ITEA PARTNER consortium consists of small to large-sized companies, universities and research institutes from across the globe. This scale of partnership allows for the implementation and continued evaluation of “connected patient” healthcare models across numerous countries, including here in Canada. Each partner brings world-leading technologies that will contribute to the new “connected patient” system, allowing all to leverage relevant expertise to tailor this novel healthcare paradigm to specific regions, thus ensuring maximum benefit to each local economy.
The European label was issued March 14, 2017, to the consortium designated as the “16017 PARTNER” project. It was issued by ITEA, a component of the EUREKA network. EUREKA’s objective is to coordinate and facilitate the activities of the European Commission and national ministries of EC countries with business, academic institutions and investors. The mandate of ITEA is to support innovations in the field of software-intensive systems and services (SiSS). ITEA’s specific mandate is to support SiSS innovations in the healthcare system.
More information about the PARTNER project, its collaborators and contact information can be found on the PARTNER project and ITEA's sites.